Morningstar: Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities MENIN inhibitors are a promising class of targeted oncology drugs in development for acute leukemias and certain solid tumors, but their use is often limited by severe dermatological side effects. Chemo rash is one of the most common side effects of cancer treatment. These rashes usually aren’t serious, but they can cause pain, itching, and other uncomfortable symptoms.
Chemotherapy, also ... The use of psychoactive drugs without medical supervision is associated with significant health risks and can lead to the development of drug use disorders. Drug use disorders, particularly when untreated, increase morbidity and mortality risks for individuals, can trigger substantial suffering and lead to impairment in personal, family, social, educational, occupational or other important ... About WHO Drug Information WHO Drug Information is a quarterly journal providing an overview of topics relating to medicines development and regulation which is targeted to a wide audience of health professionals and policy makers.
drug rash, Launched in 1987, WHO Drug Information communicates the latest international news and trends to regulatory agencies, academic and training institutions, researchers ... The Unit works globally to improve health and well-being of populations by articulating, promoting, supporting and monitoring evidence-informed policies, strategies and interventions to reduce the burden associated with alcohol, drugs and addictive behaviours. The World Health Organization (WHO) today released its Consolidated guidelines on tuberculosis (TB)- Module 4: treatment and care, consolidating all previous guidelines into a single comprehensive document and introducing significant improvements in treatment options for people with multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB).
